Advertisement

Mastocytosis

  • Arnold P. OranjeEmail author
  • Dirk Van Gysel
Chapter

Abstract

Mastocytosis is a proliferative disease of mast cells. Mastocytosis belongs to the Orphan diseases and is listed as such in the Orphanet database. Treatment is not indicated in most cutaneous variants and noncomplicated cases without complaints and/or systemic involvement. In cases with complaints or suspicion of systemic involvement, multidisciplinary approach is indicated.

Keywords

Mastocytosis Orphan disease Mastocytoma Cutaneous mastocytosis Diffuse cutaneous mastocytosis Systemic mastocytosis 

References

  1. Akin C, Metcalfe DD. The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol. 2004;114:13–9; quiz 20.CrossRefGoogle Scholar
  2. Butterfield JH. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol. 2005;114:26–40.CrossRefGoogle Scholar
  3. Carter MC, Uzzaman A, et al. Pediatric mastocytosis: routine anesthetic management for a complex disease. Anesth Analg. 2008;107:422–7.CrossRefGoogle Scholar
  4. Correia O, Duarte AF. Cutaneous mastocytosis: two pediatric cases treated with topical pimecrolimus. Dermatol Online J. 2010;16:8.PubMedGoogle Scholar
  5. Droogendijk HJ, Kluin-Nelemans HJ. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer. 2006;107:345–51.CrossRefGoogle Scholar
  6. El-Agamy DS. Targeting c-kit in the therapy of mast cell disorders: current update. Eur J Pharmacol. 2012;690:1–3.CrossRefGoogle Scholar
  7. Fuller SJ. New insights into pathogenesis, diagnosis and management of mastocytosis. Immunol Allergy Clin N Am. 2012;26:1143–68.Google Scholar
  8. Gotlib J, George TI. The KIT tyrosine kinase inhibitor midostaurine (PKC412) exhibits a high response rate in Aggressive Systemic Mastocytosis (ASM): interim results of a phase II trial. Blood (ASH Annual Meeting Abstracts). 2007;110:3536.Google Scholar
  9. Hauswirth AW, Simonitsch-Klupp I. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res. 2004;28:249–57.CrossRefGoogle Scholar
  10. Heide R, Beishuizen A, De Groot H, Den Hollander JC, Van Doormaal JJ, De Monchy JG, Pasmans SG, Van Gysel D, Oranje AP, Dutch National Mastocytosis Work Group. Mastocytosis in children: a protocol for management. Pediatr Dermatol. 2008;25:493–500.CrossRefGoogle Scholar
  11. Kluin-Nelemans HC, Oldhoff JM. Cladribine therapy for systemic mastocytosis. Blood. 2003;102:4270–6.CrossRefGoogle Scholar
  12. Ma Z, Tovar JP. Pimecrolimus induces apoptosis of mast cells in a murine model of cutaneous mastocytosis. Int Arch Allergy Immunol. 2010;153:413–8.CrossRefGoogle Scholar
  13. Rondoni M, Paolini S. Response to dasatinib in patients with aggressive systemic mastocytosis with D816V Kit mutation. Blood (ASH Annual Meeting Abstracts). 2007;110:3562.Google Scholar
  14. Siebenhaar F, Fortsch A. Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. Allergy. 2013;68:949–52.CrossRefGoogle Scholar
  15. Silva I, Carvalho S. Mastocytosis: a rare case of anaphylaxis in paediatric age and literature review. Allergol Immunopathol (Madr). 2008;36:154–63.CrossRefGoogle Scholar
  16. Simons FE, Gu X. EpiPen Jr versus EpiPen in young children weighing 15 to 30 kg at risk for anaphylaxis. J Allergy Clin Immunol. 2002;109:171–5.CrossRefGoogle Scholar
  17. Sotlar K. Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis. Verh Dtsch Ges Pathol. 2007;91:169–76.PubMedGoogle Scholar
  18. Valent P. Diagnostic evaluation and classification of mastocytosis. Immunol Allergy Clin N Am. 2006;26:515–34.CrossRefGoogle Scholar
  19. Verzijl A, Heide R, Oranje AP, van Schaik RH. c-kit Asp-816-Val mutation analysis in patients with mastocytosis. Dermatology. 2007;214(1):15–20. PubMed PMID: 17191042.CrossRefGoogle Scholar

Further Reading

  1. Akin C. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn. 2006;8:412–9.CrossRefGoogle Scholar
  2. Brockow K, Akin C, Huber M, Metcalfe DD. Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology. J Am Acad Dermatol. 2003;48:508–16.CrossRefGoogle Scholar
  3. Heide R, Zuidema E, Beishuizen A, Den Hollander JC, Van Gysel D, Seyger MM, Pasmans SG, Kakourou T, Oranje AP. Clinical aspects of diffuse cutaneous mastocytosis in children: two variants. Dermatology. 2009;219:309–15.CrossRefGoogle Scholar
  4. Heide R, van Doorn K, Mulder PG, van Toorenenbergen AW, Beishuizen A, de Groot H, Tank B, Oranje AP. Serum tryptase and SCORMA (SCORing MAstocytosis) Index as disease severity parameters in childhood and adult cutaneous mastocytosis. Clin Exp Dermatol. 2009;34:462–8.CrossRefGoogle Scholar
  5. Middelkamp Hup MA, Heide R, Tank B, Mulder PG, Oranje AP. Comparison of mastocytosis with onset in children and adults. J Eur Acad Dermatol Venereol. 2002;16:115–20.CrossRefGoogle Scholar
  6. Tefferi A, Li CY. Treatment of systemic mast-cell disease with cladribine. N Engl J Med. 2001;344:307–9.CrossRefGoogle Scholar
  7. Verstovsek S, Tefferi A. Phase II study of dasatinib (SPRYCELTM) in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Blood (ASH Annual Meeting Abstracts). 2007;110:3551.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of DermatologyMaasstad Hospital RotterdamRotterdamThe Netherlands
  2. 2.Department of PediatricsERASMUS MCRotterdamThe Netherlands
  3. 3.Department of PediatricsO.L.Vrouw HospitalAalstBelgium

Personalised recommendations